University Hospital Zurich

Telormedix receives E.U. funding for Psoriasis treatment

Tuesday, August 13, 2013

Telormedix, a clinical stage biopharmaceutical company focused on toll-like receptor 7 (TLR7) small molecules in the treatment of cancer and inflammatory diseases, has raised funding from the European Eurostars Program to coordinate an international research project involving a consortium of companies aimed at developing new formulations of one of the company’s drug candidates, TMX-302, for the treatment of psoriasis.

[Read More]